Advertisement

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

Published:September 10, 2018DOI:https://doi.org/10.1016/j.ygyno.2018.08.037

      Highlights

      • This review provides a system-based practical approach for the safe implementation of targeted and immune therapies.
      • Creation of a multidisciplinary EDDIT team can provide shared experience and enhanced patient safety.
      • Education of providers, staff, trainees, and patients is a key function of the EDDIT team.
      • Immediate access to expert advice serves to avoid delays in recognition and management of adverse events.

      Abstract

      The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pakish J.B.
        • Jazaeri A.A.
        Immunotherapy in gynecologic cancers: Are we there yet?.
        Curr. Treat. Options in Oncol. 2017; 18: 59
        • Brahmer J.R.
        • Lacchetti C.
        • Schneider B.J.
        • Atkins M.B.
        • Brassil K.J.
        • Caterino J.M.
        • et al.
        Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.
        J. Clin. Oncol. 2018; 36: 1714-1768
        • Haanen J.
        • Carbonnel F.
        • Robert C.
        • Kerr K.M.
        • Peters S.
        • Larkin J.
        • et al.
        Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2017; 28: iv119-iv142
        • Puzanov I.
        • Diab A.
        • Abdallah K.
        • Bingham C.O.
        • Brogdon C.
        • Dadu R.
        • et al.
        Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
        J. Immunother. Cancer. 2017; 5: 95
        • Yang J.C.
        • Rosenberg S.A.
        Adoptive T-cell therapy for cancer.
        Adv. Immunol. 2016; 130: 279-294
        • June C.H.
        • Sadelain M.
        Chimeric antigen receptor therapy.
        N. Engl. J. Med. 2018; 379: 64-73
        • Houot R.
        • Schultz L.M.
        • Marabelle A.
        • Kohrt H.
        T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition.
        Cancer Immunol. Res. 2015; 3: 1115-1122
        • Barrett D.M.
        • Grupp S.A.
        • June C.H.
        Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street.
        J. Immunol. 2015; 195: 755-761
        • Watanabe S.
        • Arita M.
        • Takahashi M.
        • Saida Y.
        • Koya T.
        • Kikuchi T.
        Effect of lymphodepletion on donor T cells and the role of recipient cells persisting after cytotoxic treatments in cancer immunotherapies.
        Crit. Rev. Immunol. 2017; 37: 59-73
        • Stevanovic S.
        • Draper L.M.
        • Langhan M.M.
        • Campbell T.E.
        • Kwong M.L.
        • Wunderlich J.R.
        • et al.
        Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
        J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015; 33: 1543-1550
        • Mayor P.
        • Starbuck K.
        • Zsiros E.
        Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
        Gynecol. Oncol. 2018; 150: 361-369
        • Neelapu S.S.
        • Tummala S.
        • Kebriaei P.
        • Wierda W.
        • Gutierrez C.
        • Locke F.L.
        • et al.
        Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
        Nat. Rev. Clin. Oncol. 2018; 15: 47-62